Stockreport

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical, Inc.  (CLSD) 
Last clearside biomedical, inc. earnings: 3/11 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.clearsidebio.com/investor-overview
PDF - CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside’s Proprietary SCS Microinjector® - - Topline Data Expected to be Repo [Read more]